{"id":19074,"date":"2021-09-27T09:26:05","date_gmt":"2021-09-27T07:26:05","guid":{"rendered":"https:\/\/idibell.cat\/?p=19074"},"modified":"2021-09-27T09:26:05","modified_gmt":"2021-09-27T07:26:05","slug":"un-nou-farmac-incrementa-lesperanca-de-vida-dels-pacients-amb-un-cancer-intraocular-molt-agressiu","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/09\/un-nou-farmac-incrementa-lesperanca-de-vida-dels-pacients-amb-un-cancer-intraocular-molt-agressiu\/","title":{"rendered":"Un nou f\u00e0rmac incrementa l\u2019esperan\u00e7a de vida dels pacients amb un c\u00e0ncer intraocular molt agressiu"},"content":{"rendered":"<p>El melanoma uveal \u00e9s el c\u00e0ncer intraocular m\u00e9s com\u00fa. Igual que els melanomes cutanis, \u00e9s degut a la proliferaci\u00f3 descontrolada dels melan\u00f2cits, les c\u00e8l\u00b7lules que donen color a la pell. Per\u00f2 a difer\u00e8ncia d&#8217;aquests, el melanoma uveal, que representa entre el 3 i el 5% dels melanomes, presenta caracter\u00edstiques moleculars i cel\u00b7lulars que el fan especialment agressiu. La meitat dels pacients desenvolupen met\u00e0stasis, i quan aix\u00f2 passa <strong>l&#8217;esperan\u00e7a de vida mitjana no supera l&#8217;any<\/strong>. Fins ara, cap dels tractaments actuals ha aconseguit millorar-ne el pron\u00f2stic.<\/p>\n<p>Un estudi publicat avui a la prestigiosa revista <em>cient\u00edfica <\/em><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2103485\"><em>The New England Journal of Medicine<\/em><\/a>, que ha comptat amb la participaci\u00f3 del <strong>Dr. Josep Maria Piulats<\/strong> de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/immunoterapia-del-cancer\/\">IDIBELL<\/a>), l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO) i el Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), ha presentat el <strong>primer f\u00e0rmac que allarga l&#8217;esperan\u00e7a de vida total dels pacients amb melanoma uveal <\/strong>quan aquests ja han desenvolupat met\u00e0stasi.<\/p>\n<p>L&#8217;estudi, corresponent a un assaig cl\u00ednic en fase 3 en el qual s&#8217;ha avaluat l&#8217;efic\u00e0cia i seguretat del nou f\u00e0rmac anomenat <strong>Tebentafusp<\/strong>, demostra que el tractament proposat aconsegueix alentir la progressi\u00f3 de la malaltia ja que el percentatge de pacients que sobreviuen m\u00e9s d&#8217;un any passa del 58% amb els tractaments est\u00e0ndards, al 73% amb Tebentafusp. El <strong>Dr. Piulats<\/strong>, coordinador del programa Oncobell de l&#8217;IDIBELL i de l&#8217;ICO, destaca: &#8220;<em>despr\u00e9s de finalitzar aquest estudi i dels bons resultats augmentant la superviv\u00e8ncia global dels gaireb\u00e9 \u00a0400 pacients inclosos en l\u2019assaig, el Tebentausp ja s\u2019est\u00e0 donant als pacients amb melanomes uveals metast\u00e0tics en substituci\u00f3 de la quimioter\u00e0pia habitual\u201d.<\/em><\/p>\n<p><strong>\u00a0<\/strong><strong>\u00a0<\/strong><\/p>\n<h4>Tebentafusp, una guia del sistema immunitari per atacar tumors s\u00f2lids<\/h4>\n<p>El Tebentafusp actua guiant al sistema immunitari cap al tumor. Est\u00e0 format per dos extrems: un reconeix les c\u00e8l\u00b7lules tumorals i l&#8217;altre s&#8217;uneix a les c\u00e8l\u00b7lules del sistema immunitari i les activa. D&#8217;aquesta manera s&#8217;aconsegueix que les c\u00e8l\u00b7lules immunit\u00e0ries &#8220;vegin&#8221; el tumor i a m\u00e9s l&#8217;ataquin.<\/p>\n<p>&#8220;<em>La tecnologia desenvolupada per generar el Tebentafusp permet que el sistema immunitari ataqui espec\u00edficament el tumor sense necessitat de recon\u00e8ixer-lo<\/em> \u2013explica el <strong>Dr. Piulats<\/strong>\u2013. <em>O sigui, no cal que les c\u00e8l\u00b7lules del sistema immunitari tinguin receptors espec\u00edfics que reconeguin les c\u00e8l\u00b7lules tumorals, el mateix f\u00e0rmac fa de mediador perqu\u00e8 aquestes l&#8217;ataquin<\/em>&#8220;.<\/p>\n<p>Es tracta del primer medicament amb aquestes caracter\u00edstiques que s&#8217;ha provat en tumors s\u00f2lids. A m\u00e9s, al tractar-se d\u2019un f\u00e0rmac que reconeix espec\u00edficament les c\u00e8l\u00b7lules tumorals no afecta a teixits no desitjats i comporta <strong>menys efectes secundaris que els tractaments est\u00e0ndards amb quimioter\u00e0pia<\/strong>. No obstant, tal com indica el <strong>Dr. Piulats<\/strong>: \u201c<em>L\u2019administraci\u00f3 d\u2019aquest f\u00e0rmac requereix d\u2019experi\u00e8ncia per identificar les possibles toxicitats derivades i actuar en conseq\u00fc\u00e8ncia per evitar-les<\/em>\u201d.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Els resultats de l&#8217;assaig cl\u00ednic, publicats al the New England Journal of Medicine, mostren que el Tebentafusp \u00e9s el primer f\u00e0rmac a augmentar la superviv\u00e8ncia global  en el melanoma uveal mestat\u00e0tic, un c\u00e0ncer molt agressiu que en el 50% dels casos provoca la mort en menys d\u2019un any.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,453,447,452],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-11 16:37:32","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19074"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=19074"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19074\/revisions"}],"predecessor-version":[{"id":19076,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19074\/revisions\/19076"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=19074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=19074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=19074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}